<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:arxiv="http://arxiv.org/schemas/atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>q-bio.CB updates on arXiv.org</title>
    <link>http://rss.arxiv.org/rss/q-bio.CB</link>
    <description>q-bio.CB updates on the arXiv.org e-print archive.</description>
    <atom:link href="http://rss.arxiv.org/rss/q-bio.CB" rel="self" type="application/rss+xml"/>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <language>en-us</language>
    <lastBuildDate>Wed, 08 Oct 2025 04:01:02 +0000</lastBuildDate>
    <managingEditor>rss-help@arxiv.org</managingEditor>
    <pubDate>Wed, 08 Oct 2025 00:00:00 -0400</pubDate>
    <skipDays>
      <day>Sunday</day>
      <day>Saturday</day>
    </skipDays>
    <item>
      <title>Deciphering the Role of Acetate in Metabolic Adaptation and Osimertinib Resistance in Non-Small Cell Lung Cancer</title>
      <link>https://arxiv.org/abs/2510.05920</link>
      <description>arXiv:2510.05920v1 Announce Type: cross 
Abstract: Aims. Resistance to targeted therapies remains a major challenge in EGFR-mutant non-small cell lung cancer (NSCLC). Here, we describe a novel metabolic adaptation in osimertinib-resistant cells characterized by elevated acetate levels and activation of an unconventional pyruvate-acetaldehyde-acetate (PAA) shunt. Methods. Integrated transcriptomic, exometabolomic, and functional analyses reveal suppression of canonical metabolic pathways and upregulation of ALDH2 and ALDH7A1, that mediate the NADP+-dependent oxidation of acetaldehyde to acetate, generating NADPH. Results. This shift generates reducing power essential for biosynthesis and redox balance under conditions of oxidative pentose phosphate inhibition. These metabolic changes promote endurance in resistant cells and rewire the interplay between glycolysis, the pentose phosphate pathway, and the tricarboxylic acid cycle, offering a de novo bypass for anaplerosis and bioenergetics. Systematic metabolite profiling revealed distinct transcriptomic and metabolic signatures distinguishing resistant from drug sensitive parental cells. Conclusions. Together, these findings depict a unique, resistance-driven adaptive metabolic shift and uncover potential therapeutic vulnerabilities in osimertinib-resistant NSCLC.</description>
      <guid isPermaLink="false">oai:arXiv.org:2510.05920v1</guid>
      <category>q-bio.SC</category>
      <category>q-bio.CB</category>
      <pubDate>Wed, 08 Oct 2025 00:00:00 -0400</pubDate>
      <arxiv:announce_type>cross</arxiv:announce_type>
      <dc:rights>http://arxiv.org/licenses/nonexclusive-distrib/1.0/</dc:rights>
      <dc:creator>Giorgia Maroni (Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche ITB CNR, Pisa, Italy), Eva Cabrera San Millan (Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche ITB CNR, Pisa, Italy), Beatrice Campanella (Istituto di Chimica dei Composti Organo Metallici ICCOM CNR Pisa, Italy), Massimo Onor (Istituto di Chimica dei Composti Organo Metallici ICCOM CNR Pisa, Italy), Giovanni Cercignani (Scuola Normale di Pisa, Class of Sciences, Pisa, Italy), Beatrice Muscatello (Dipartimento di Farmacia, University of Pisa and CISUP, Pisa, Italy), Giulia Braccini (Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche ITB CNR, Pisa, Italy), Raffaella Mercatelli (Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche ITB CNR, Pisa, Italy), Alice Chiodi (Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche ITB CNR, Pisa, Italy), Ettore Mosca (Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche ITB CNR, Pisa, Italy), Elena Levantini (Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche ITB CNR, Pisa, Italy), Emilia Bramanti (Istituto di Chimica dei Composti Organo Metallici ICCOM CNR Pisa, Italy)</dc:creator>
    </item>
    <item>
      <title>Design principles of the cytotoxic CD8+ T-cell response</title>
      <link>https://arxiv.org/abs/2509.22997</link>
      <description>arXiv:2509.22997v2 Announce Type: replace-cross 
Abstract: Cytotoxic T lymphocytes eliminate infected or malignant cells, safeguarding surrounding tissues. Although experimental and systems-immunology studies have cataloged many molecular and cellular actors involved in an immune response, the design principles governing how the speed and magnitude of T-cell responses emerge from cellular decision-making remain elusive. Here, we recast the T-cell response as a feedback-controlled program, wherein the rates of activation, proliferation, differentiation and death are regulated through antigenic, pro- and anti-inflammatory cues. By exploring a broad class of feedback-controller designs as potential immune programs, we demonstrate how the speed and magnitude of T-cell responses emerge from optimizing signal-feedback to protect against diverse infection settings. We recover an inherent trade-off: infection clearance at the cost of immunopathology. We show how this trade-off is encoded into the logic of T-cell responses by hierarchical sensitivity to different immune signals. Notably, we find that designs that balance harm from acute infections and autoimmunity produce immune responses consistent with experimentally observed patterns of T-cell effector expansion in mice. Extending our model to immune-based T-cell therapies for cancer tumors, we identify a trade-off between the affinity for tumor antigens ("quality") and the abundance ("quantity") of infused T-cells necessary for effective treatment. Finally, we show how therapeutic efficacy can be improved by targeted genetic perturbations to T-cells. Our findings offer a unified control-logic for cytotoxic T-cell responses and point to specific regulatory programs that can be engineered for more robust T-cell therapies.</description>
      <guid isPermaLink="false">oai:arXiv.org:2509.22997v2</guid>
      <category>physics.bio-ph</category>
      <category>q-bio.CB</category>
      <pubDate>Wed, 08 Oct 2025 00:00:00 -0400</pubDate>
      <arxiv:announce_type>replace-cross</arxiv:announce_type>
      <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
      <dc:creator>Obinna A. Ukogu, Zachary Montague, Gr\'egoire Altan-Bonnet, Armita Nourmohammad</dc:creator>
    </item>
  </channel>
</rss>
